Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Peptic Ulcer

  Free Subscription


Articles published in J Gastroenterol

Retrieve available abstracts of 29 articles:
HTML format



Single Articles


    March 2024
  1. KURIBAYASHI S, Nakamura F, Motegi SI, Hara K, et al
    Prevalence and risk factors for medication-refractory reflux esophagitis in patients with systemic sclerosis in Japan.
    J Gastroenterol. 2024;59:179-186.
    PubMed     Abstract available


    February 2024
  2. HUANG Y, Lu H
    Reply to: Minocycline versus tetracycline in bismuth-containing quadruple therapy for Helicobacter pylori rescue treatment: a multicentre, randomized controlled trial.
    J Gastroenterol. 2024 Feb 14. doi: 10.1007/s00535-024-02085.
    PubMed    


    January 2024
  3. LEECH T, Peiris M
    Mucosal neuroimmune mechanisms in gastro-oesophageal reflux disease (GORD) pathogenesis.
    J Gastroenterol. 2024 Jan 14. doi: 10.1007/s00535-023-02065.
    PubMed     Abstract available


    December 2023
  4. ICHITA C, Goto T, Shimizu S
    Considerations for evaluating antibiotic prophylaxis in cirrhotic patients with upper gastrointestinal bleeding in real-world data.
    J Gastroenterol. 2023 Dec 19. doi: 10.1007/s00535-023-02066.
    PubMed    


  5. UENO M, Fujiwara T, Tokumasu H, Mizuno M, et al
    Reply to "Considerations for evaluating antibiotic prophylaxis in cirrhotic patients with upper gastrointestinal bleeding in real-world data".
    J Gastroenterol. 2023 Dec 13. doi: 10.1007/s00535-023-02067.
    PubMed    


    November 2023
  6. KAWAGUCHI T, Okamoto K, Fujimoto S, Bando M, et al
    Lansoprazole inhibits the development of sessile serrated lesions by inducing G1 arrest via Skp2/p27 signaling pathway.
    J Gastroenterol. 2023 Nov 22. doi: 10.1007/s00535-023-02052.
    PubMed     Abstract available


    October 2023
  7. KOTANI S, Shibagaki K, Hirahara N, Hasegawa N, et al
    Clinicopathologic differences of gastric neoplasms between Helicobacter pylori-infected and -naive patients: a multicenter retrospective analysis.
    J Gastroenterol. 2023 Oct 19. doi: 10.1007/s00535-023-02050.
    PubMed     Abstract available


  8. HAN YY, Zhou L, Hu YL, Ding XW, et al
    Comparison of vonoprazan-based with rabeprazole-based dual therapy for treatment-naive patients of Helicobacter pylori infection: a prospective, multi-center, randomized controlled study.
    J Gastroenterol. 2023 Oct 1. doi: 10.1007/s00535-023-02042.
    PubMed     Abstract available


    July 2023
  9. WATANABE K, Iijima K
    Risk of pneumonia associated with proton pump inhibitor use.
    J Gastroenterol. 2023 Jul 16. doi: 10.1007/s00535-023-02022.
    PubMed    


    June 2023
  10. HIRAI R, Hirai M, Otsuka M, Mitsuhashi T, et al
    Endoscopic evaluation by the Kyoto classification of gastritis combined with serum anti-Helicobacter pylori antibody testing reliably risk-stratifies subjects in a population-based gastric cancer screening program.
    J Gastroenterol. 2023 Jun 21. doi: 10.1007/s00535-023-02010.
    PubMed     Abstract available


  11. MARET-OUDA J, Panula J, Santoni G, Xie S, et al
    Proton pump inhibitor use and risk of pneumonia: a self-controlled case series study.
    J Gastroenterol. 2023 Jun 14. doi: 10.1007/s00535-023-02007.
    PubMed     Abstract available


    May 2023
  12. UENO M, Fujiwara T, Tokumasu H, Mano T, et al
    Real-world efficacy of antibiotic prophylaxis for upper gastrointestinal bleeding in cirrhotic patients in Japan.
    J Gastroenterol. 2023 May 12. doi: 10.1007/s00535-023-02000.
    PubMed     Abstract available


    April 2023
  13. HUANG Y, Chen J, Ding Z, Chen X, et al
    Minocycline vs. tetracycline in bismuth-containing quadruple therapy for Helicobacter pylori rescue treatment: a multicentre, randomized controlled trial.
    J Gastroenterol. 2023 Apr 12. doi: 10.1007/s00535-023-01991.
    PubMed     Abstract available


  14. KATO M, Hosoe N, Gotoda T, Kusano C, et al
    Treatment with vonoprazan for 3 weeks is not inferior to 8 weeks for the management of gastric ESD: a multicenter noninferiority randomized study.
    J Gastroenterol. 2023;58:358-366.
    PubMed     Abstract available


    December 2022
  15. KAKIUCHI T, Matsuo M, Endo H, Sakata Y, et al
    Efficacy and safety of vonoprazan-based regimen for Helicobacter pylori eradication therapy in Japanese adolescents: a prospective multicenter study.
    J Gastroenterol. 2022 Dec 17. doi: 10.1007/s00535-022-01942.
    PubMed     Abstract available


  16. WALDUM H
    Risk of gastric and oesophageal adenocarcinomas following discontinuation of long-term proton-pump inhibitor therapy.
    J Gastroenterol. 2022 Dec 17. doi: 10.1007/s00535-022-01943.
    PubMed    


  17. HOLMBERG D, Lagergren J
    Risk of gastric and oesophageal adenocarcinoma following discontinuation of long-term proton-pump inhibitor therapy.
    J Gastroenterol. 2022 Dec 14. doi: 10.1007/s00535-022-01941.
    PubMed    


    October 2022
  18. SONG L, Song M, Rabkin CS, Chung Y, et al
    Identification of anti-Helicobacter pylori antibody signatures in gastric intestinal metaplasia.
    J Gastroenterol. 2022 Oct 27. pii: 10.1007/s00535-022-01933.
    PubMed     Abstract available


  19. HOLMBERG D, Mattsson F, Xie S, Ness-Jensen E, et al
    Risk of gastric and oesophageal adenocarcinoma following discontinuation of long-term proton-pump inhibitor therapy.
    J Gastroenterol. 2022 Oct 18. pii: 10.1007/s00535-022-01930.
    PubMed     Abstract available


    August 2022
  20. AKAZAWA Y, Ueyama H, Hayashi T, Utsunomiya H, et al
    Clinicopathological and molecular characterization of early gastric adenocarcinoma in Helicobacter pylori-uninfected patients: emphasis on differentiated gastric adenocarcinoma.
    J Gastroenterol. 2022 Aug 8. pii: 10.1007/s00535-022-01906.
    PubMed     Abstract available


    June 2022
  21. ITO M, Sugiyama A, Mino M, Kodama M, et al
    Prevalence of Helicobacter pylori infection in the general population evaluated by a resident-register-based epidemiological study.
    J Gastroenterol. 2022 Jun 20. pii: 10.1007/s00535-022-01885.
    PubMed     Abstract available


    February 2022
  22. IWAKIRI K, Fujiwara Y, Manabe N, Ihara E, et al
    Evidence-based clinical practice guidelines for gastroesophageal reflux disease 2021.
    J Gastroenterol. 2022 Feb 28. pii: 10.1007/s00535-022-01861.
    PubMed     Abstract available


    August 2021
  23. FUKUCHI T, Hirasawa K, Sato C, Makazu M, et al
    Potential roles of gastroesophageal reflux in patients with superficial esophageal squamous cell carcinoma without major causative risk factors.
    J Gastroenterol. 2021 Aug 23. pii: 10.1007/s00535-021-01815.
    PubMed     Abstract available


    June 2021
  24. MATSUHASHI T, Hatta W, Hikichi T, Fukuda S, et al
    A simple prediction score for in-hospital mortality in patients with nonvariceal upper gastrointestinal bleeding.
    J Gastroenterol. 2021 Jun 18. pii: 10.1007/s00535-021-01797.
    PubMed     Abstract available


    February 2021
  25. KAMADA T, Satoh K, Itoh T, Ito M, et al
    Evidence-based clinical practice guidelines for peptic ulcer disease 2020.
    J Gastroenterol. 2021 Feb 23. pii: 10.1007/s00535-021-01769.
    PubMed     Abstract available


  26. LAI SW
    Proton pump inhibitors and the risk of pancreatic cancer.
    J Gastroenterol. 2021 Feb 5. pii: 10.1007/s00535-021-01764.
    PubMed    


  27. BRUSSELAERS N, Sadr-Azodi O, Engstrand L
    Proton pump inhibitors and the risk of pancreatic cancer.
    J Gastroenterol. 2021 Feb 2. pii: 10.1007/s00535-021-01761.
    PubMed    


    November 2020
  28. IBANEZ-SANZ G, Mila N, de la Pena-Negro LC, Garcia M, et al
    Proton-pump inhibitors are associated with a high false-positivity rate in faecal immunochemical testing.
    J Gastroenterol. 2020 Nov 7. pii: 10.1007/s00535-020-01738.
    PubMed     Abstract available


  29. ROGERS B, Samanta S, Ghobadi K, Patel A, et al
    Artificial intelligence automates and augments baseline impedance measurements from pH-impedance studies in gastroesophageal reflux disease.
    J Gastroenterol. 2020 Nov 5. pii: 10.1007/s00535-020-01743.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Peptic Ulcer is free of charge.